Organigram Holdings Announces Annual and Fourth Quarter Results for Fiscal 2015

Organigram attains Breakeven cash flow in Q1

MONCTON, New Brunswick (December 18, 2015) – Organigram Holdings Inc. (TSX-V) today reported results for the year and fourth quarter ended August 31, 2015.



Business Outlook

The company sales for Quarter 1, ending November 30, 2015, exceeded $1,000,000, representing over a 70% increase quarter to quarter.

The company sales for the week ending December 11, 2015, were approximately $120,000. This sales milestone provides the company with an adequate level of cash flow which exceeds their current operating expenses. Management is very pleased to have attained positive cash flow so early in their infancy.

The company exceeded their targets for this fiscal year from a revenue and customer acquisition basis. They focused on solidifying their production capabilities and ensuring a superior customer experience. They completed Phase 3 of their build out and now have 7 large grow rooms in production of a potential 13 within the existing facility.

As the next fiscal year unfolds, the company has many of the same targets but only on a much larger scale. However, in conjunction with this, the company will continue to implement solid business practices and policies which will ensure structure and stability. The Company’s key short-term goals continue to include:

  • Complete the construction (Phase 4 & 5) and receive Health Canada approval of an additional 6 large grow rooms within the existing facility. This will add an additional 1,500kg of annual production capacity, which will bring its annual capacity to over 3,100 kg.
  • Continual efforts on education within the Medical Community.
  • A focused effort on cost control throughout the organization and a further reduction on production costs per gram.
  • To continue to generate positive cash flow from operations.
  • Ensure the company is well positioned for legalization from a production and branding perspective.
  • Complete the expansion of the Company’s facility by connecting the adjacent building and starting phase 6 & 7 of the development plan. This will access an additional 12 grow rooms and provide annual production capabilities of approximately 7,500 kilograms.

The company has grown significantly over the past year, achieved many milestones and met all commitments. The industry is evolving at a rapid rate and it is our intention to be prepared for these changes as they occur. We continue to streamline our systems and processes for efficiency and optimization of resources. It is the company’s opinion that those producers who can maximize their product margins will be the leaders in the industry as it exists today and if legalization occurs.

The Company has secured an additional $6.4 million of financing which will enable them to continue their expansion, provide additional working capital and to continue to onboard clients at a rapid rate.

Fourth quarter ended August 31, 2015 

  • Current Assets at quarter-end was $4.6 million while current liabilities were $1.7 million, for a net working capital position of $2.9 million.
  • Quarterly revenue was $675,530, an increase of 194% from the $230,053 recorded for the previous quarter.
  • Sales gross margin percentage, before indirect production and fair value adjustment to biological assets, for the quarter was 63%, and also 63% for the year.
  • Net income was $56,926 for the quarter, compared to a net income of 119,695 for the prior quarter.

Non-GAAP Financial Measures

In this news release, the Company uses the non-GAAP financial measure EBITDA. The Company believes these non-GAAP financial measures provide useful information to both management and investors in measuring the financial performance of the Company. These measures do not have a standardized meaning prescribed by GAAP and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies, and should not be construed as an alternative to other financial measures determined in accordance with GAAP.

Forward-Looking Statements

Certain information herein contains or incorporates comments that constitute forward-looking information within the meaning of applicable securities legislation. Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans”, or “continue”, or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, projections or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities; and, statements regarding our future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which, by their nature are inherently uncertain and beyond management control. We have based these forward-looking statements on our current expectations about future events.

Although the forward-looking statements contained in this news release are based on what we believe are reasonable assumptions, these assumptions are subject to a number of risks beyond the Company’s control and there can be no assurance that actual results will be consistent with these forward-looking statements. Factors that could cause actual results to differ materially from those set forth in the forward-looking statements and information include, but are not limited to: financial risks; dependence on senior management; sufficiency of insurance; industry competition; general economic conditions and global events; product development, facility and technological risks; changes to government laws, regulations or policy, including environmental or tax, or the enforcement thereof; agricultural risks; supply risks; product risks; and, other risks and factors described from time to time in the documents filed by the Company with securities regulators.

All forward-looking information is provided as of the date of this news release. The Company does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required by law. Additional information about these assumptions, risks and uncertainties is contained in our filings with securities regulators. Certain filings are also available on our website at

Financial statements can be viewed by clicking here

Have a question for us?

Call 1-844-644-4726 (1-844-OGI-GRAM) and the folks on our client support team like Dan, Janice and Jeff can answer any question you have.

Monday to Thursday: 8:30 AM to 8:00 PM 
Friday: 8:30 AM to 6:30 PM 
Fax: 1-855-267-1386

Stay informed. #DiscoverOGI.

Interested in keeping up with Organigram news? Subscribe to our mailing lists and stay up-to-date on Organigram products, patient programs, company news and investor relations. 

By signing up, I acknowledge that I can unsubscribe at any time, and I accept the terms, conditions and privacy policy.

If you wish to receive newsletters from Organigram Holdings Inc. and its subsidiaries, please provide your email address and click on the “Subscribe” button above. If we do not receive your consent, we may be unable to send you communications. If you have any questions, or if you wish to withdraw your consent at any time, please feel free to contact us by phone at 1-844-644-4726 or by email at By clicking “Subscribe” I consent to receipt of communications as indicated above.